We found that the double-control chimeric siRNA had no effect on cancer cell viability (Figure 8A and Supplemental Figure 13A), further confirming that the potent decrease of cell viability following treatment of the MYC/KRAS inverted chimeric siRNA was due to specific knockdown of the genes of interest. This evidence concerns the gene MYC and cancer.